Neurogene (NGNE) Stock
Clinical stage biotech developing new immune system treatments. Here's the price, business snapshot, and what's worth knowing about Neurogene in June 2026.
Neoleukin Therapeutics, Inc. (NGNE) is a clinical‑stage biotechnology company focused on designing de novo protein therapeutics intended to modulate the immune system. The firm engineers novel protein scaffolds that mimic natural cytokines with the aim of improving anti‑cancer immune responses while reducing side effects seen with native molecules. As a small‑cap company (market capitalisation around $450.6M), Neoleukin’s value is driven largely by early clinical data, regulatory progress and partnerships rather than steady revenue. Investing in such companies involves binary outcomes — positive trial results can materially increase value, while setbacks or funding challenges can lead to sharp declines. Investors should monitor trial updates, cash runway disclosed in SEC filings, and scientific readouts, and be aware this is high‑risk, speculative exposure. This is educational information and not personalised investment advice; suitability depends on your risk tolerance and portfolio goals.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Neurogene's stock, anticipating significant growth ahead.
Financial Health
Neurogene Inc. is performing well with strong cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NGNE
RNA Stocks (M&A Targets) Could See Premium Valuations
Novartis's $12 billion acquisition of Avidity Biosciences underscores the high value of RNA-based treatments for rare diseases. This deal could spark a wave of similar acquisitions, creating opportunities for other biotech companies with innovative RNA platforms.
Published: 27 October 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: 30 July 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: 21 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
De novo protein design
Neoleukin’s engineered proteins aim to replicate immune signalling with potential safety benefits, though clinical proof is still evolving and outcomes are uncertain.
Data‑driven moves
Share direction often follows clinical readouts and regulatory news; trial results can create sharp moves in either direction.
Watch funding and partners
Cash runway and collaborations shape long‑term prospects; small‑cap biotech financing needs can dilute shareholders if additional capital is required.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
